Vaccine therapy in hematologic malignancies
نویسندگان
چکیده
منابع مشابه
Targeted therapy for hematologic malignancies.
BACKGROUND The introduction of monoclonal antibodies, either as native molecules or conjugated to radioisotopes or other toxins, has led to new therapeutic options for patients with hematologic malignancies. In addition, the use of small molecules against specific cell surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders. METHODS The aut...
متن کاملInterleukin-2 in therapy of hematologic malignancies.
T HE ARTICLE BY Gisselbrecht et all in this issue of Blood describes the activity of single-agent interleukin-2 (IL-2) in a heterogeneous group of previously treated patients with malignant non-Hodgkin’s lymphoma (NHL), Hodgkin’s disease, and cutaneous T-cell lymphoma (CTCL). The number of patients within each of the defined groups is relatively small, and the confidence intervals surrounding t...
متن کاملCAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens
Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...
متن کاملAmbulatory antimicrobial therapy for hematologic malignancies.
Risk prediction in patients with neutropenia and fever in a reliable and timely manner has only become possible in the last decade. Patients have been categorized as high risk or low risk based on certain presenting characteristics. Low-risk patients may be defined as hemodynamically stable, with responsive or controlled malignancies, brief (< or = 7-day) periods of neutropenia, and no signific...
متن کاملNonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
Much of the therapeutic benefit of allogeneic transplant is by a graft versus tumor effect. Further data shows that transplant engraftment is not dependant on myeloablation, instead relying on quantitative competition between donor and host cells. In the clinical setting, engraftment by competition alone is not feasible due to the need for large numbers of infused cells. Instead, low-level host...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2018
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2017-11-785873